Elekta AB (publ) (LON:0O5H)
London · Delayed Price · Currency is GBP · Price in SEK | Market Cap | 1.71B +16.5% |
| Revenue (ttm) | 1.41B -4.3% |
| Net Income | -3.29M |
| EPS | -0.01 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | 14.15 |
| Dividend | 0.19 (0.34%) |
| Ex-Dividend Date | Mar 5, 2026 |
| Volume | 39,572 |
| Average Volume | 355,586 |
| Open | 57.35 |
| Previous Close | 56.90 |
| Day's Range | 56.15 - 57.30 |
| 52-Week Range | 42.20 - 66.60 |
| Beta | 0.96 |
| RSI | 53.62 |
| Earnings Date | May 28, 2026 |
About Elekta AB
Elekta AB (publ), a medical technology company, provides clinical solutions for treating cancer and brain disorders in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers linear accelerator and radiation therapy products comprising Elekta Unity for anatomy-specific MR imaging; Elekta Evo that delivers offline and online adaptive radiation therapy; Elekta Versa HD, a brain metastases solution; Elekta Harmony; and Elekta Infinity for treating a range of patients with simple-to-complex radiotherapy needs, as wel... [Read more]
Financial Performance
In fiscal year 2025, Elekta AB's revenue was 18.02 billion, a decrease of -0.57% compared to the previous year's 18.12 billion. Earnings were 237.00 million, a decrease of -81.80%.
Financial numbers in SEK Financial StatementsNews
Elekta downgraded to Sell from Hold at Danske Bank
Danske Bank analyst Erik Cassel downgraded Elekta (EKTAY) to Sell from Hold with a SEK 45 price target
Elekta price target raised to SEK 60 from SEK 49 at Deutsche Bank
Deutsche Bank raised the firm’s price target on Elekta (EKTAY) to SEK 60 from SEK 49 and keeps a Hold rating on the shares.
Elekta price target lowered to SEK 52 from SEK 61 at JPMorgan
JPMorgan analyst David Adlington lowered the firm’s price target on Elekta (EKTAY) to SEK 52 from SEK 61 and keeps an Underweight rating on the shares.
Elekta initiated with a Sell at UBS
UBS analyst Kavya Deshpande initiated coverage of Elekta (EKTAY) with a Sell rating and SEK 34 price target The firm’s analysis suggests the radiotherapy market is slowing meaningfully and that…
Elekta price target lowered to SEK 48 from SEK 49.50 at Barclays
Barclays lowered the firm’s price target on Elekta (EKTAY) to SEK 48 from SEK 49.50 and keeps an Underweight rating on the shares.
Elekta price target lowered to SEK 39 from SEK 51.50 at Citi
Citi lowered the firm’s price target on Elekta (EKTAY) to SEK 39 from SEK 51.50 and keeps a Sell rating on the shares.
Elekta downgraded to Hold from Buy at Danske Bank
Danske Bank downgraded Elekta (EKTAY) to Hold from Buy with a SEK 53 price target
Elekta price target lowered to SEK 47 from SEK 57 at JPMorgan
JPMorgan lowered the firm’s price target on Elekta (EKTAY) to SEK 47 from SEK 57 and keeps an Underweight rating on the shares.
Elekta price target lowered to SEK 55 from SEK 57 at Morgan Stanley
Morgan Stanley lowered the firm’s price target on Elekta (EKTAY) to SEK 55 from SEK 57 and keeps an Underweight rating on the shares.
Elekta downgraded to Hold from Buy at Danske Bank
Danske Bank downgraded Elekta (EKTAY) to Hold from Buy with a SEK 55 price target
Elekta price target lowered to SEK 57 from SEK 63 at JPMorgan
JPMorgan analyst David Adlington lowered the firm’s price target on Elekta (EKTAY) to SEK 57 from SEK 63 and keeps an Underweight rating on the shares.
Elekta price target lowered to SEK 57.50 from SEK 64.50 at Barclays
Barclays lowered the firm’s price target on Elekta (EKTAY) to SEK 57.50 from SEK 64.50 and keeps an Underweight rating on the shares.
Elekta upgraded to Market Perform from Underperform at Bernstein
Bernstein analyst Lisa Bedell Clive upgraded Elekta (EKTAY) to Market Perform from Underperform with a SEK 69 price target The firm says consensus estimates now reflect the company’s margin headwinds…
Elekta price target raised to SEK 65 from SEK 63 at Barclays
Barclays raised the firm’s price target on Elekta (EKTAY) to SEK 65 from SEK 63 and keeps an Underweight rating on the shares.
ZAP Surgical Deals Two More Blows to Elekta in IP Suit, Removing Barriers to Mass Adoption of the ZAP-X Radiosurgery Platform
SAN CARLOS, Calif.--(BUSINESS WIRE)--ZAP Surgical Systems, Inc., a leading innovator in the field of surgical robotics, has achieved significant legal victories in its ongoing patent litigation agains...
St George's Cancer Care Centre Becomes First Elekta Unity Site to Integrate ClearCalc
NEW YORK & CHRISTCHURCH, New Zealand--(BUSINESS WIRE)--St George's Cancer Care Centre is the first cancer center in the world to leverage ClearCalc from Radformation with Elekta's MR-Linac technology.
Elekta: Interim report, May-January 2021/22
STOCKHOLM, Feb. 24, 2022 /PRNewswire/ -- The demand for Elekta's solutions continued to be strong in the third quarter, the fifth consecutive quarter with underlying order growth, resulting in Elekta'...
Elekta announces preliminary third quarter results
STOCKHOLM, Feb. 14, 2022 /PRNewswire/ -- Elekta (EKTA-B.ST) today published preliminary financial results for the third quarter 2021/22. The demand for Elekta's precision radiation medicine solutions ...
Invitation to the presentation of Elekta's third quarter 2021/22
STOCKHOLM, Feb. 4, 2022 /PRNewswire/ -- Elekta (EKTA-B.ST) invites analysts and investors to a presentation of the third quarter 2021/22 at 10:00 a.m. CET on February 24.
Elekta increases customer focus with direct presence in Philippines
STOCKHOLM, Feb. 2, 2022 /PRNewswire/ -- Elekta (EKTA-B.ST) announced today that it has established an office in the Philippines' capital, Manila, to offer new and existing customers superior service, ...
Elekta to appoint Tobias Hägglöv as Chief Financial Officer
STOCKHOLM, Jan. 7, 2022 /PRNewswire/ -- Elekta (STO: EKTA-B) announced today that it will appoint Tobias Hägglöv as Chief Financial Officer effective February 1, 2022, taking over from Johan Adebäck. ...
Elekta's new sustainability-linked bond oversubscribed
STOCKHOLM, Dec. 3, 2021 /PRNewswire/ -- Elekta (EKTA-B.ST) announced today that it has issued SEK 1.5 billion senior unsecured sustainability-linked bonds under its Medium Term Note Program (MTN-Progr...
More cancer patients in Africa to benefit from advanced radiation therapy with Elekta Unity MR-Linac
STOCKHOLM, Nov. 25, 2021 /PRNewswire/ -- Elekta (EKTA-B.ST) announced today that its latest African order for Elekta Unity MR-Linac comes less than six months after the company introduced its ACCESS 2...
Elekta: Interim report, May-October 2021/22
STOCKHOLM, Nov. 25, 2021 /PRNewswire/ -- The increasing need for investments in cancer care and radiotherapy across the globe supported a gradual market recovery during the quarter. Our orders grew wi...
Invitation to the presentation of Elekta's second quarter 2021/22
STOCKHOLM, Nov. 4, 2021 /PRNewswire/ --Elekta (EKTA-B.ST) invites analysts and investors to a presentation of the second quarter 2021/22 at 10:00 a.m. CET on November 25.